Patents by Inventor Huabing Yang

Huabing Yang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20260055188
    Abstract: A bispecific antibody, including: a first antibody or antigen-binding fragment thereof that specifically binds to a first antigen; and a second antibody or antigen-binding fragment thereof that specifically binds to a second antigen; where the first antigen is a tumor-associated antigen (TAA), and the second antigen is TNFR2. The bispecific antibody can target a tumor-associated antigen (TAA), and at the same time can stimulate the proliferation of CD8+ T cells, activate CD8+ T cells, and release anti-tumor factors such as IFN? and IL2 by using a TNFR2 agonistic antibody; or can block TNF-TNFR2 and inhibit the proliferation of Treg by using a TNFR2 antagonistic antibody.
    Type: Application
    Filed: August 18, 2023
    Publication date: February 26, 2026
    Applicant: SHENGHE (CHINA) BIOPHARMACEUTICAL CO., LTD.
    Inventors: Jinhua ZHOU, Chong ZHOU, Chongbing WU, Xiaoling JIANG, Liusong YIN, Huabing YANG
  • Publication number: 20260055201
    Abstract: A bispecific antibody, including: (a) a first antibody or antigen-binding fragment thereof that specifically binds to a first antigen; and (b) a second antibody or antigen-binding fragment thereof that specifically binds to a second antigen; where the first antigen is a T cell immunomodulator, and the second antigen is TNFR2. The bispecific antibody is a T cell regulator of tumor microenvironment, which can stimulate the proliferation of CD8+T cells, activate CD8+T cells, and release anti-tumor factors, such as IFN? and IL2 by using a TNFR2 agonistic antibody; or can block TNF-TNFR2 and inhibit the proliferation of Treg by using a TNFR2 antagonistic antibody. At the same time, it can further relieve immunosuppression, increase the number of anti-tumor cells and solve the limitation of heterogeneity of TME by cooperating with T cell immunomodulator at the target or systemic system.
    Type: Application
    Filed: August 18, 2023
    Publication date: February 26, 2026
    Applicant: SHENGHE (CHINA) BIOPHARMACEUTICAL CO., LTD.
    Inventors: Chong ZHOU, Jinhua ZHOU, Chongbing WU, Xiaoling JIANG, Liusong YIN, Huabing YANG
  • Publication number: 20260028401
    Abstract: Provided is an anti-ILT4 single-domain antibody and antigen-binding fragment thereof. Also provided are a method of using it for the treatment or prevention of a disease in a subject, and a method of preparing the antibody and antigen-binding fragment thereof.
    Type: Application
    Filed: July 28, 2023
    Publication date: January 29, 2026
    Applicant: SHENGHE (CHINA) BIOPHARMACEUTICAL CO., LTD.
    Inventors: Huabing YANG, Liusong YIN, Xiaoling JIANG
  • Patent number: 11266668
    Abstract: A formulation for a dietary supplement includes standardized extracts of astragalus root, phlorizin, root bark of white mulberry, olive leaf, and bitter melon. The formulation may further include chromium, 2-deoxy-D-glucose, biotin, vitamin D and vitamin C. A method of controlling postprandial blood glucose includes administering the formulation for the dietary supplement to a patient.
    Type: Grant
    Filed: February 14, 2020
    Date of Patent: March 8, 2022
    Assignee: WORLD PHARMACEUTICAL TECHNOLOGY, LLC
    Inventors: Yong Wu, Wei Cao, Jieqing Li, Huabing Yang, Ke Wu, Shiliu Tian
  • Patent number: 11135259
    Abstract: Compositions for improving erectile function or treating erectile dysfunction include active ingredients of Muira Puama extract, Quercetin, Chlorophytum borivilianum (Safed Musli), Dimethylethanolamine (DMAE), niacin, Tribulus terrestris extract, alpha-lipoic acid, Horny Goat Weed (Epimedium grandfiflorum), Panax ginseng, and saw palmetto berry extract, and may also include magnesium aspartate, Zinc oxide, and Maca root (Lepidium meyenii). Additional active ingredients include Avena sativa extract (oat straw), L-Taurine, L-Lysine hydrochloride (HCl), a L-Arginine, and/or L-Carnitine.
    Type: Grant
    Filed: January 3, 2019
    Date of Patent: October 5, 2021
    Assignee: WORLD PHARMACEUTICAL TECHNOLOGY, LLC
    Inventors: Yong Wu, Ke Wu, Gordon Lee, Wei Cao, Huabing Yang
  • Patent number: 10757961
    Abstract: A formulation for a dietary supplement includes standardized extracts of Astragalus root, phlorizin, root bark of white mulberry, olive leaf, and bitter melon. The formulation may further include chromium, 2-deoxy-D-glucose, biotin, vitamin D and vitamin C. A method of controlling postprandial blood glucose includes administering the formulation for the dietary supplement to a patient.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: September 1, 2020
    Assignee: WORLD PHARMACEUTICAL TECHNOLOGY, LLC.
    Inventors: Yong Wu, Wei Cao, Jieqing Li, Huabing Yang, Ke Wu, Shiliu Tian
  • Publication number: 20200197429
    Abstract: A formulation for a dietary supplement includes standardized extracts of astragalus root, phlorizin, root bark of white mulberry, olive leaf, and bitter melon. The formulation may further include chromium, 2-deoxy-D-glucose, biotin, vitamin D and vitamin C. A method of controlling postprandial blood glucose includes administering the formulation for the dietary supplement to a patient.
    Type: Application
    Filed: February 14, 2020
    Publication date: June 25, 2020
    Inventors: Yong Wu, Wei Cao, Jieqing Li, Huabing Yang, Ke Wu, Shiliu Tian
  • Publication number: 20200146325
    Abstract: A formulation for a dietary supplement includes standardized extracts of astragalus root, phlorizin, root bark of white mulberry, olive leaf, and bitter melon. The formulation may further include chromium, 2-deoxy-D-glucose, biotin, vitamin D and vitamin C. A method of controlling postprandial blood glucose includes administering the formulation for the dietary supplement to a patient.
    Type: Application
    Filed: December 21, 2018
    Publication date: May 14, 2020
    Inventors: Yong Wu, Wei Cao, Jieqing Li, Huabing Yang, Ke Wu, Shiliu Tian
  • Publication number: 20190365842
    Abstract: Compositions for improving erectile function or treating erectile dysfunction include active ingredients of Muira Puama extract, Quercetin, Chlorophytum Borivilianum (Safed Musli), Dimethylethanolamine (DMAE), niacin, Tribulus Terrestris extract, alpha-lipoic acid, Horny Goat Weed (Epimedium grandfiflorum), Panax ginseng, and saw palmetto berry extract, and may also include magnesium aspartate, Zinc oxide, and Maca root (Lepidium meyenii). Additional active ingredients include Avena Sativa extract (oat straw), L-Taurine, L-Lysine hydrochloride (HCl), a L-Arginine, and/or L-Carnitine.
    Type: Application
    Filed: January 3, 2019
    Publication date: December 5, 2019
    Inventors: Yong Wu, Ke Wu, Gordon Lee, Wei Cao, Huabing Yang